Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
Janux Therapeutics, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/14/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/08/2023 |
8-K
| Quarterly results|
Docs:
|
"Janux Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights - Presented positive interim Phase 1 clinical trial data for PSMA-TRACTr JANX007 in prostate cancer - Management team bolstered with key appointment - $303.3 million in cash, cash equivalents, and short-term investments at end of second quarter 2023 - In July, further strengthened balance sheet with approximately $60 million offering SAN DIEGO, August 8, 2023 – Janux Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager and Tumor Activated Immunomodulator platforms, today reported financial results for the second quarter ended June 30, 2023, and provided a business..." |
|
| 07/18/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 07/18/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Underwriting Agreement, between the Company and BofA Securities, Inc.",
"Form of Pre-Funded Warrant",
"Opinion of Cooley LLP",
"Janux Therapeutics Announces Pricing of $60 Million Underwritten Offering of Common Stock and Pre-Funded Warrants SAN DIEGO, July 17, 2023 - Janux Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager and Tumor Activated Immunomodulator platforms, today announced the pricing of an underwritten offering of 4,153,717 shares of its common stock and pre-funded warrants to purchase 583,483 shares of common stock. The shares of common stock are being sold at a price of $12.46 per share and the pre-funded warrants are being sold at a price of $12.459 per pre-funded warrant, which represents the per share price for the common stock less the $0.001 per share ex..." |
|
| 07/17/2023 |
FWP
| Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses: |
| 07/17/2023 |
8-K
| Quarterly results |
| 07/10/2023 |
SC 13G
| CITADEL ADVISORS LLC reports a 5.1% stake in Janux Therapeutics, Inc. |
| 05/30/2023 |
SC 13G
| BIOTECHNOLOGY VALUE FUND L P reports a 9.8% stake in Janux Therapeutics, Inc. |
| 05/09/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 05/09/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/09/2023 |
8-K
| Quarterly results |
| 04/28/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/28/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/31/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/10/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/10/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/10/2023 |
8-K
| Quarterly results |
| 02/10/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/09/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/09/2023 |
SC 13G/A
| FMR LLC reports a 13.5% stake in JANUX THERAPEUTICS INC |
| 09/22/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"Janux Therapeutics Appoints Winston Kung to Board of Directors SAN DIEGO, September 22, 2022 – Janux Therapeutics, Inc. , a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager and Tumor Activated Immunomodulator platforms, today announced the appointment of Winston Kung to the Company’s Board of Directors. Janux also announced that Stefan Heller, Ph.D., who has served on Janux’s Board since 2018, has resigned. These changes are effective immediately. “On behalf of the Board and leadership of Janux, I would like to thank Stefan for providing his guidance and expertise over the last four years,” said David Campbell, Ph.D., President and CEO of Janux. "I’d also like to wel..." |
|
| 09/20/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 06/14/2022 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/10/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 05/10/2022 |
8-K
| Quarterly results |
| 05/02/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 03/18/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/18/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
| 03/18/2022 |
8-K
| Quarterly results |
| 02/11/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/11/2022 |
SC 13G
| Campbell David Alan reports a 5.5% stake in Janux Therapeutics, Inc., a Delaware corporation |
|
|
|